Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.65 Analyst target: $15.20 Upside: 316.44%
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS) and other diseases. The company is headquartered in Daix, France.
See the full interactive analysis & chart →Informational only — not investment advice.